Physician profile
Scot Randall
NPI 1881611465
$2,157.09
in general payments reported to CMS, 2019-2025
26 companies · $94.79 in 2025
The $94.79 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $111 · 2021: $340 · 2022: $563 · 2023: $224 · 2024: $296 · 2025: $94.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $296.31 | 2022-2024 | Caplyta |
| Novo Nordisk INC | $252.52 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $245.77 | 2019 | |
| Amgen INC. | $183.18 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $155.10 | 2019-2023 | |
| Abbvie INC. | $154.48 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.68 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $125.54 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $122.57 | 2019-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $85.14 | 2019-2021 | |
| Glaxosmithkline, LLC. | $65.02 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Eisai INC. | $35.51 | 2021 | |
| Boston Scientific Corporation | $30.41 | 2024 | |
| Merck Sharp & Dohme LLC | $28.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.96 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $25.73 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.04 | 2024 | Rexulti |
| Lilly USA, LLC | $22.81 | 2020 | |
| Axsome Therapeutics, INC. | $20.37 | 2025 | Auvelity |
| Daiichi Sankyo INC. | $18.08 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.78 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.56 | 2022 | |
| Phadia US INC. | $14.82 | 2021 | |
| Adlon Therapeutics L.P. | $13.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.16 | 2019 | |
| Ascend Therapeutics US, LLC | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scot Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.